Blog

Slide background
Slide background
Slide background
Slide background
Slide background
Slide background
Slide background
Slide background
Slide background

Celentyx

Celentyx are looking to raise £2m to develop novel targeted therapeutic antibodies for immuno-oncology and immune-mediated disease. Importantly, these antibodies recognise their target protein as presented by human native cells in health and disease.

www.celentyx.com